JP2008505060A5 - - Google Patents

Info

Publication number

JP2008505060A5

JP2008505060A5 JP2007513872A JP2007513872A JP2008505060A5 JP 2008505060 A5 JP2008505060 A5 JP 2008505060A5 JP 2007513872 A JP2007513872 A JP 2007513872A JP 2007513872 A JP2007513872 A JP 2007513872A JP 2008505060 A5 JP2008505060 A5 JP 2008505060A5

Authority

JP

Japan

Prior art keywords

patient

slc6a3

gene

polymorphism

vntr

Prior art date

2005-06-03

Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)

Pending

Links

• Espacenet
• Global Dossier
• Discuss

• 101150085000 SLC6A3 gene Proteins 0.000 claims description 16
• QZUDBNBUXVUHMW-UHFFFAOYSA-N clozapine Chemical compound C1CN(C)CCN1C1=NC2=CC(Cl)=CC=C2NC2=CC=CC=C12 QZUDBNBUXVUHMW-UHFFFAOYSA-N 0.000 claims description 13
• 229960004170 clozapine Drugs 0.000 claims description 13
• 238000000034 method Methods 0.000 claims description 8
• 210000001124 body fluid Anatomy 0.000 claims description 6
• 239000010839 body fluid Substances 0.000 claims description 5
• 239000002773 nucleotide Substances 0.000 claims description 5
• 125000003729 nucleotide group Chemical group 0.000 claims description 5
• 108020005345 3' Untranslated Regions Proteins 0.000 claims description 4
• 206010010144 Completed suicide Diseases 0.000 claims description 4
• 101000639972 Homo sapiens Sodium-dependent dopamine transporter Proteins 0.000 claims description 3
• 239000003814 drug Substances 0.000 claims description 3
• 108091036066 Three prime untranslated region Proteins 0.000 claims description 2
• 201000000980 schizophrenia Diseases 0.000 claims description 2
• 108700028369 Alleles Proteins 0.000 claims 9
• 108010044266 Dopamine Plasma Membrane Transport Proteins Proteins 0.000 claims 8
• 102000005029 SLC6A3 Human genes 0.000 claims 8
• 206010065604 Suicidal behaviour Diseases 0.000 claims 5
• 108090000623 proteins and genes Proteins 0.000 claims 5
• 230000003252 repetitive effect Effects 0.000 claims 4
• 239000000090 biomarker Substances 0.000 claims 3
• 239000003550 marker Substances 0.000 claims 3
• 102220284259 rs1379395211 Human genes 0.000 claims 3
• 239000000523 sample Substances 0.000 claims 3
• 108091034117 Oligonucleotide Proteins 0.000 claims 2
• 102100033928 Sodium-dependent dopamine transporter Human genes 0.000 claims 2
• 238000011084 recovery Methods 0.000 claims 2
• 230000004043 responsiveness Effects 0.000 claims 2
• 108020004414 DNA Proteins 0.000 claims 1
• 239000008280 blood Substances 0.000 claims 1
• 210000004369 blood Anatomy 0.000 claims 1
• 238000004519 manufacturing process Methods 0.000 claims 1
• 239000000203 mixture Substances 0.000 claims 1
• 239000013610 patient sample Substances 0.000 claims 1
• 230000035945 sensitivity Effects 0.000 claims 1
• 101150076975 DAT1 gene Proteins 0.000 description 3
• 230000014509 gene expression Effects 0.000 description 3
• 229940079593 drug Drugs 0.000 description 2
• 102000054765 polymorphisms of proteins Human genes 0.000 description 2
• FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 1
• 208000027534 Emotional disease Diseases 0.000 description 1
• 108091023045 Untranslated Region Proteins 0.000 description 1
• 210000000349 chromosome Anatomy 0.000 description 1
• 238000002483 medication Methods 0.000 description 1
• 230000002974 pharmacogenomic effect Effects 0.000 description 1
• 230000002265 prevention Effects 0.000 description 1
• 230000000698 schizophrenic effect Effects 0.000 description 1
• 210000001519 tissue Anatomy 0.000 description 1